AP32788: Phase I/II started

Ariad began an open-label, U.S. Phase I/II trial of oral AP32788 in about 105

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE